SRPT (Sarepta Therapeutics) Current Deferred Revenue: $110 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SRPT Sarepta Therapeutics Inc SRPT
59 GF Score
Price $18.10
GF Value $109.36
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Sarepta Therapeutics Current Deferred Revenue?

Sarepta Therapeutics SRPT -1.71% 59 Current Deferred Revenue is $110 Mil as of Jun. 2026. GuruFocus rates SRPT with a GF Score™ of 59/100 and a GF Value™ of $109.36 (Possible Value Trap). The stock has 3 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Sarepta Therapeutics's current deferred revenue for the quarter that ended in Jun. 2026 was $110 Mil.

Sarepta Therapeutics Current Deferred Revenue Related Terms

Sarepta Therapeutics Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Sarepta Therapeutics's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sarepta Therapeutics Current Deferred Revenue Chart

Sarepta Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 89.24 89.24 50.42 130.26 443.40

Sarepta Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 395.43 485.45 443.40 116.04 110.13
SRPT
59GF Score
Sarepta Therapeutics Inc SRPT
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of $110 Mil mean?
Sarepta Therapeutics (SRPT) has a Current Deferred Revenue of $110 Mil as of Jun. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Sarepta Therapeutics and its competitors.
Is Sarepta Therapeutics' Current Deferred Revenue too high?
Sarepta Therapeutics' current Current Deferred Revenue is $110 Mil. Overall, Sarepta Therapeutics has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sarepta Therapeutics' Current Deferred Revenue compare to MPLT and ZYME?
Sarepta Therapeutics' Current Deferred Revenue of $110 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Sarepta Therapeutics and its competitors. Sarepta Therapeutics's current Current Deferred Revenue is $110 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sarepta Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Sarepta Therapeutics (SRPT) is currently considered Possible Value Trap. The stock's GF Value™ is $109.36, compared to a current price of $18.10 — trading 83.4% below its estimated fair value. The current Current Deferred Revenue is $110 Mil. Sarepta Therapeutics' overall GF Score™ is 59/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Sarepta Therapeutics (SRPT), the current Current Deferred Revenue is $110 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sarepta Therapeutics (SRPT) Overvalued in 2026?

Based on GuruFocus' analysis, Sarepta Therapeutics stock appears to be undervalued. The current stock price of $18.10 is trading 83.4% below its estimated GF Value™ of $109.36. GuruFocus considers Sarepta Therapeutics to be Possible Value Trap.

Key valuation signals for SRPT:

  • Current Deferred Revenue: $110 Mil
  • GF Value™: $109.36 vs. price of $18.10 (83.4% below fair value)
  • GF Score™: 59/100 with 3 warning signs

No single metric tells the full story. See the SRPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sarepta Therapeutics Business Description

Address 215 First Street, Suite 415, Cambridge, MA, USA, 02142
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
59GF Score

Get the complete analysis for SRPT

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.10
Price
$109.36
GF Value